MDT

87.15

-1.56%↓

A

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

A

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

A

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

A

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

A

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

Search

Charles River Laboratories International Inc

Abrir

SetorSaúde

172.77 0.19

Visão Geral

Variação de preço das ações

24h

Atual

Mín

172.62

Máximo

175.9

Indicadores-chave

By Trading Economics

Rendimento

-332M

-277M

Vendas

-11M

994M

Margem de lucro

-27.816

Funcionários

18,300

EBITDA

730K

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+17.6% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

359M

8.3B

Abertura anterior

172.58

Fecho anterior

172.77

Sentimento de Notícias

By Acuity

16%

84%

36 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de abr. de 2026, 00:00 UTC

Notícias Principais

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10 de abr. de 2026, 00:00 UTC

Notícias Principais

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10 de abr. de 2026, 00:00 UTC

Notícias Principais

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10 de abr. de 2026, 00:00 UTC

Notícias Principais

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10 de abr. de 2026, 00:00 UTC

Notícias Principais

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10 de abr. de 2026, 00:00 UTC

Notícias Principais

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10 de abr. de 2026, 00:00 UTC

Notícias Principais

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10 de abr. de 2026, 00:00 UTC

Notícias Principais

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10 de abr. de 2026, 00:00 UTC

Notícias Principais

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10 de abr. de 2026, 00:00 UTC

Notícias Principais

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9 de abr. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9 de abr. de 2026, 23:34 UTC

Conversa de Mercado

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9 de abr. de 2026, 23:14 UTC

Conversa de Mercado

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9 de abr. de 2026, 23:14 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

9 de abr. de 2026, 23:07 UTC

Conversa de Mercado

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9 de abr. de 2026, 22:54 UTC

Conversa de Mercado

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9 de abr. de 2026, 22:31 UTC

Notícias Principais

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9 de abr. de 2026, 22:31 UTC

Notícias Principais

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9 de abr. de 2026, 20:57 UTC

Notícias Principais

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9 de abr. de 2026, 20:55 UTC

Ganhos

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 de abr. de 2026, 20:55 UTC

Ganhos

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 de abr. de 2026, 20:55 UTC

Ganhos

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

9 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de abr. de 2026, 20:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9 de abr. de 2026, 20:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9 de abr. de 2026, 20:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Rowan Digital Infrastructure Announces Strategic Recapitalization

9 de abr. de 2026, 20:25 UTC

Aquisições, Fusões, Aquisições de Empresas

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 de abr. de 2026, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

9 de abr. de 2026, 19:30 UTC

Notícias Principais

How Digital Currencies Have Helped Iran -- WSJ

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

17.6% parte superior

Previsão para 12 meses

Média 205.89 USD  17.6%

Máximo 265 USD

Mínimo 175 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

8

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

36 / 348 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat